Core Viewpoint - Xianju Pharmaceutical announced a one-year extension for its fundraising project "High-end Formulation Internationalization Construction Project" while maintaining the project’s implementation subject, location, funding purpose, and investment scale unchanged [1][2] Group 1: Project Details - The total committed investment amount for the "High-end Formulation Internationalization Construction Project" is 700 million yuan, with 636 million yuan already invested as of October 31, 2025, representing a progress of 90.79% [1] - The remaining funds will be used for civil construction, cleanroom facilities, equipment warranty payments, and supporting testing facilities required for the formal production phase of certain products [1] - The project’s main buildings have completed construction and received acceptance reports for environmental protection, fire safety, and safety inspections [1] Group 2: Reasons for Delay - The project’s timeline has been extended from December 31, 2025, to December 31, 2026, due to pending approvals for some declared products and the production lines not yet being officially operational [2] - The company aims to strategically position itself for capacity expansion in high-end formulation international products, which involves establishing a new formulation technology platform [2] - The nature of pharmaceutical research, characterized by long cycles, multiple stages, and high technical difficulty, contributes to the uncertainty in the approval timeline for product formulations [2] Group 3: Financial Performance - Xianju Pharmaceutical has faced declining performance, with revenue and net profit both decreasing for two consecutive years in 2023 and 2024 [3] - For the first three quarters of this year, the company reported revenue of 2.826 billion yuan, a year-on-year decrease of 12.71%, and a net profit attributable to shareholders of 407 million yuan, down 23.29% year-on-year [3] Group 4: Regulatory Issues - In September, the company and its chairman received warning letters due to violations related to the misuse of raised funds, including not following proper review procedures and using raised funds for unrelated expenses [4] - The Zhejiang Securities Regulatory Bureau held the chairman and other executives responsible for these violations and decided to implement supervisory measures, including warning letters [4]